Patients with an earlier age of hepatoblastoma onset (≤1.25 years) who are double positive for membranous EpCAM and nuclear β-catenin in tumors have a better response to chemotherapy and better long-term outcomes. Here, EPCAM is linked to hepatoblastoma.